Navigation Links
Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
Date:5/15/2009

comprehensive clinical development program evaluating carfilzomib for the treatment of multiple myeloma, including an ongoing accelerated approval study in heavily pre-treated relapsed/refractory patients and a Phase 2 trial in relapsed patients. A Phase Ib clinical trial of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, Proteolix is conducting a single-agent Phase 2 clinical trial of carfilzomib in patients with recurrent or advanced solid tumors. For the latest information regarding ongoing carfilzomib clinical trials, please visit www.clinicaltrials.gov.

About Proteolix

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Proteolix is also developing a pipeline of novel proteasome inhibitors, including a selective, oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit www.proteolix.com.


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
4. Proteolix Raises $79 Million in Series C Financing
5. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
8. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
9. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
10. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
11. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced ... for use as a once-daily adjunctive therapy for the ... are not satisfactorily controlled with conventional therapy.  APTIOM TM ... 18 years of age. Epilepsy is ... to Epilepsy Canada, it affects 0.6% of the population ...
(Date:7/10/2014)... Product and process impurities in ... and are often “lost in the noise,” making ... presenters Dr. Rowel Tobias, Senior Scientist, Protein Chemistry ... of Quality at Nanotherapeutics, Inc., to lear about ... detection and quantitation while achieving the required specificity ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Unraveling life’s ... together. The Archer Family purchased a DNA ... DNA, but ended up with a lifetime of memories, ... within the family members’ DNA genuinely brought the family ... to search deeper into genetic history and prior to ...
(Date:7/10/2014)... Calabasas, CA (PRWEB) July 10, 2014 ... academic institutions and professional associations, addressed the challenges of ... & Medical Device Industries” through strategic sourcing. Describing the ... ) with the Supply Chain Management Institute ( SCMI) ... the event on June 24 at the Kroc Institute ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... TherapySAN FRANCISCO, May 21 Gualberto Ruano, M.D., ... Research at Hartford Hospital and Simon Kung, M.D., ... will co-chair a symposium, " Emerging Clinical Applications ... the annual meeting of the American Psychiatric Association. ...
... AMSTERDAM, May 21 ,Agendia, a world leader in molecular ... University of California San Francisco ,and the Netherlands ... American Society of Clinical Oncology Annual Meeting, May 29 ... The study results further underpin the broad ...
... Sky One Medical,Inc. ("China Sky One Medical" or ... leading,fully integrated pharmaceutical company in the People,s Republic ... agreement with Taiwan Golden,Biotechnology Corporation to begin cooperating ... Antroquinonol. , Golden Biotechnology ...
Cached Biology Technology:Genomas and Institute of Living Among Organizers of Pharmacogenetics Symposium at 2009 Annual Meeting of the American Psychiatric Association 2Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting 2Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting 3China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug 2China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug 3
(Date:7/11/2014)... is creating a new professorship in tissue engineering ... for Molecular Engineering and the Marine Biological Laboratory, ... Millicent and Eugene Bell Foundation., The Eugene Bell ... Institute for Molecular Engineering. That endowed chair holder ... MBL,s Eugene Bell Center for Regenerative Biology and ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... 2014 The increased risk of kidney injury related ... fluids reflects the mass of HES molecules, according to ... journal of the International Anesthesia Research Society (IARS). , ... effect of HES on cultured human renal proximal tubule ... Wunder and colleagues of University Hospital Wrzburg, Austria. ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2A new genome editing method brings the possibility of gene therapies closer to reality 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... at Washington University in St. Louis is giving the ... more clues about our biological clock. , VIP is ... a neuropeptide originally found in the gut, that is ... the brain. , Erik Herzog, Ph.D., Washington University assistant ...
... appreciated as a disease of the genes, cancer is ... regulation. Scientists have identified some of the first genetic ... tumor suppressor genes. Full-blown tumors and metastatic cancers, however, ... given tumor. An important scientific question, and one with ...
... an Australian first, UNSW researchers have developed three clones of ... lead to new treatments for diabetes, Parkinson's disease and spinal ... technique, which is a very accurate way of extracting and ... Kuldip Sidhu, who is leading the research and is based ...
Cached Biology News:Discovery clarifies role of peptide in biological clock 2Unchecked DNA replication drives earliest steps toward cancer 2Unchecked DNA replication drives earliest steps toward cancer 3Stem cell research - new cell lines 2
... Well Plate Sterile with ... range of 384-well plates ... screening and research. These ... and are suitable for ...
Request Info...
... to Cytokeratin 5 / 6 Cytokeratin ... weight, basic type of cytokeratin expressed in ... layers of stratified epithelia as well as ... cells and mesothelioma. Cytokeratin 6 (56 kD) ...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Biology Products: